Evidence-based Interventions for Youth With Concurrent Mental Health and Substance Use Disorders: A Scoping Review: Interventions fondées sur des données probantes pour les jeunes atteints de troubles concomitants de santé mentale et liés à l'usage de substances psychoactives : une étude de la portée.

Background: Mental health and substance use disorders typically onset during youth and commonly co-occur. Integrated treatment of two or more co-existing mental health and substance use disorders (i.e.

Early identification of children with Attention-Deficit/Hyperactivity Disorder (ADHD).

Signs and symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) are present at preschool ages and often not identified for early intervention. We aimed to use machine learning to detect ADHD early among kindergarten-aged children using population-level administrative health data and a childhood developmental vulnerability surveillance tool: Early Development Instrument (EDI). The study cohort consists of 23,494 children born in Alberta, Canada, who attended kindergarten in 2016 without a diagnosis of ADHD.

Impact of psilocybin on cognitive function: A systematic review.

Psilocybin is a classic psychedelic with demonstrated preliminary clinical efficacy in a range of psychiatric disorders. Evaluating the impact of psilocybin on cognitive function is essential to unravel its potential benefits and risks. In this systematic review, we assessed psilocybin's effect on cognitive function through a comprehensive search of electronic databases from inception to January 2024, identifying 20 articles involving 2,959 participants.

Do beta-amyloid-targeted interventions improve cognition, physical functioning, and overt behaviour of Alzheimer's Disease (AD) patients: Protocol for meta-analysis of Phase 3 clinical trials both completed and terminated.

Accumulation of amyloid-beta (Aβ) in the brain has been explored as a primary cause of Alzheimer's Disease (AD). Better known as the amyloid hypothesis, it has been the main target of researchers vying to bring their therapeutic interventions to market despite several failed attempts by predecessors. In June 2021, Aduhelm (Aducanumab) became the first U.